Verducatib clinical trials
Also written BI 1291583.
How each study uses verducatib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the verducatib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2025 (4); 2 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 1 in phase 3
Studies that test verducatib, phase 3 first.
- Jun 2027The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisPhase 3 · Boehringer Ingelheim
- Dec 2026A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the BloodPhase 1 · Boehringer Ingelheim
- Dec 2026A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver ProblemsPhase 1 · Boehringer Ingelheim
- Dec 2026A Study in Healthy People to Measure How Different Doses of Verducatib Affect the HeartPhase 1 · Boehringer Ingelheim
- Mar 2027Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This MedicinePhase 2 · Boehringer Ingelheim
Studies
Open first, then newest update. How each study uses verducatib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Not yet recruitingPhase 3Boehringer IngelheimNCT07915219Written as verducatib
- The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisRecruitingPhase 3Boehringer IngelheimNCT06872892Written as BI 1291583
- The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary DiseaseNot yet recruitingPhase 3Boehringer IngelheimNCT07907991Written as Verducatib
- A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver ProblemsRecruitingPhase 1Boehringer IngelheimNCT07023354Written as BI 1291583
- A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the BloodRecruitingPhase 1Boehringer IngelheimNCT07781631Written as Verducatib
- A Study in Healthy People to Measure How Different Doses of Verducatib Affect the HeartActive, not recruitingPhase 1Boehringer IngelheimNCT07760246Written as Verducatib
- A Study in Healthy Men to Test How BI 1291583 is Taken up by the BodyCompletedPhase 1Boehringer IngelheimNCT06166992Written as BI 1291583
- Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This MedicineActive, not recruitingPhase 2Boehringer IngelheimNCT05846230Written as BI 1291583
- A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese ParticipantsCompletedPhase 1Boehringer IngelheimNCT07531628Written as Verducatib
- A Study to Test Whether Different Doses of BI 1291583 Help People With BronchiectasisCompletedPhase 2Boehringer IngelheimNCT05238675Written as BI 1291583
- A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)CompletedPhase 2Boehringer IngelheimNCT05865886Written as BI 1291583
- A Study in Healthy Men to Test How BI 1291583 is Processed in the BodyCompletedPhase 1Boehringer IngelheimNCT05833035Written as BI 1291583 mixed with [C-14] BI 1291583
- A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the BloodCompletedPhase 1Boehringer IngelheimNCT06917872Written as BI 1291583
- A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are ToleratedCompletedPhase 1Boehringer IngelheimNCT04866160Written as BI 1291583
- A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different FormulationsCompletedPhase 1Boehringer IngelheimNCT06631417Written as BI 1291583
- A Study to Test How Food Influences the Amount of BI 1291583 in the Blood of Healthy MenCompletedPhase 1Boehringer IngelheimNCT03837964Written as BI 1291583
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the BloodCompletedPhase 1Boehringer IngelheimNCT03890887Written as BI 1291583
- A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are ToleratedCompletedPhase 1Boehringer IngelheimNCT05183347Written as BI 1291583
- A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the BodyCompletedPhase 1Boehringer IngelheimNCT06791187Written as BI 1291583
- A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are ToleratedTerminatedPhase 1Boehringer IngelheimNCT03868540Written as BI 1291583
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
- A Study in Healthy Men to Test How BI 1291583 is Taken up by the BodyNov 9, 2026NCT06166992
Newly registered2
Codes
What other systems call verducatib · ClinicalTrials.gg INT017202
- UNII (FDA) LPO8EV0QNSVERDUCATIBConfirmed FDA, Wikidata
- Wikidata Q140529364verducatibConfirmed FDA, Wikidata
- NCI Thesaurus C215781VerducatibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LPO8EV0QNS | VERDUCATIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529364 | verducatib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C215781 | Verducatib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.